Bisphosphocin

Lakewood-Amedex CEO to Present Bisphosphocin Data at Three Investor Events

Lakewood-Amedex CEO to Present Bisphosphocin Data at Three Investor Events

Sarasota, Fla. – October 01, 2026 -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) will send CEO Kelvin Cooper, Ph.D., to three separate industry conferences this month, placing the clinical-stage antimicrobial developer in front of both investors and infectious-disease specialists within an eight-day window.

CEO to address investor audiences at two New York events in mid-October

Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City, followed by a presentation at the ThinkEquity Conference on October 15, 2026, also in New York City. Both appearances target biotechnology investors evaluating the company's pipeline.

Lakewood-Amedex CEO to Present at H.C. Wainwright Conference

Lakewood-Amedex CEO to Present at H.C. Wainwright Conference

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

CEO Kelvin Cooper to hold one-on-one investor meetings during three-day conference

Kelvin Cooper, Ph.D., chief executive officer of the clinical-stage biotechnology company, will deliver a virtual presentation and conduct one-on-one meetings with registered investors and potential partners. The sessions will cover Lakewood-Amedex's business and clinical development strategy, recent corporate achievements, and anticipated milestones.